MannKind is trading at $3.12, down 5.16%, with no clear catalyst identified for the October 12 decline. - Latest company news was supportive Furoscix ReadyFlow clinical data announced October 9, not an evident negative trigger. - Major indexes were nearly flat, offering no clear broad-market explanation for the drop. - Truist’s October 7 Buy-rating decision cut its price target from $6 to $5, but predates the session and does not establish the cause.